Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.72 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL420148 | 1.00 | MCHR1 (0.72) | MCHR1BACE1CYP4F2CYP4A11CNR2 | |
| SCHEMBL415260 | 0.86 | MCHR1 (0.54) | MCHR1 | |
| SCHEMBL415259 | 0.86 | MCHR1 (0.54) | MCHR1 | |
| SCHEMBL418820 | 0.86 | MCHR1 (0.71) | MCHR1 | |
| SCHEMBL418821 | 0.86 | MCHR1 (0.71) | MCHR1 | |
| SCHEMBL10083297 | 0.85 | MCHR1 (0.82) | MCHR1BACE1ACACB | |
| SCHEMBL10083298 | 0.84 | MCHR1 (1.00) | MCHR1BACE1GPR119 | |
| SCHEMBL10083302 | 0.81 | MCHR1 (0.82) | MCHR1BACE1CNR2 | |
| SCHEMBL10083299 | 0.81 | MCHR1 (0.77) | MCHR1CYP3A4 | |
| SCHEMBL10083316 | 0.81 | MCHR1 (0.76) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552199-B2 | Substituted indanes, method for the production thereof, and use thereof as drugs | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-20120022039-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022039-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | MCHR1, MCHR2, IDO1 | MCHR1 1/4885BACE1 3623/4885CYP4F2 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.